PubRank

Bipin N Savani

Author PubWeight™ 73.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2007 2.29
2 High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006 2.21
3 Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013 2.17
4 Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013 1.88
5 Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 2011 1.88
6 Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013 1.80
7 First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012 1.74
8 Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007 1.61
9 Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013 1.54
10 Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005 1.37
11 Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2008 1.31
12 Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007 1.28
13 Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2010 1.27
14 Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Haematologica 2010 1.23
15 Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. Semin Hematol 2012 1.22
16 Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008 1.18
17 Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010 1.14
18 Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2010 1.11
19 Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010 1.08
20 Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2010 1.04
21 Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012 1.03
22 T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 2006 1.00
23 Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012 0.98
24 High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 2007 0.97
25 Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010 0.95
26 Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant 2011 0.94
27 Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013 0.93
28 Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp Hematol 2012 0.92
29 Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013 0.92
30 Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2008 0.92
31 The role of nutrition and effects on the cytokine milieu in allogeneic hematopoietic stem cell transplantation. Cell Immunol 2012 0.92
32 Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant 2011 0.92
33 Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant 2013 0.91
34 Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010 0.90
35 Providing personalized prognostic information for adult leukemia survivors. Biol Blood Marrow Transplant 2013 0.89
36 Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant 2012 0.88
37 Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 2013 0.87
38 Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010 0.86
39 Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. Expert Rev Hematol 2013 0.86
40 Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2007 0.86
41 Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp Hematol 2012 0.85
42 Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 2011 0.85
43 Recovery of spermatogenesis after total-body irradiation. Blood 2006 0.85
44 Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother 2011 0.85
45 Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood 2012 0.85
46 Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. Exp Hematol 2012 0.84
47 Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2012 0.83
48 Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009 0.83
49 Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2011 0.83
50 Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD? Blood 2009 0.83
51 How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation? Exp Hematol 2012 0.82
52 Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant 2012 0.82
53 Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant. Int J Radiat Oncol Biol Phys 2006 0.82
54 New allergies after cord blood transplantation. Cytotherapy 2013 0.82
55 Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. Biol Blood Marrow Transplant 2013 0.81
56 Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007 0.79
57 Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood 2011 0.79
58 How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. Eur J Haematol 2014 0.79
59 Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Exp Hematol 2012 0.79
60 Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006 0.78
61 Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 2005 0.78
62 Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Eur J Haematol 2014 0.78
63 Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol 2005 0.78
64 HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012 0.78
65 High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Implications for Differentiating Agents in APL and Metabolic Syndrome. Ther Adv Hematol 2011 0.78
66 Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009 0.77
67 Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation. Cytotherapy 2010 0.76
68 Understanding basic steps to hematopoietic stem cell transplantation evaluation. Am J Blood Res 2013 0.75
69 Prophylactic intravenous immunoglobulin does not have a role in hematopoietic stem-cell transplantation: is the evidence clear? J Clin Oncol 2009 0.75
70 Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation. Clin Lymphoma Myeloma Leuk 2012 0.75
71 Response to "What is the optimal approach to major ABO-incompatible allogeneic stem cell transplantation". Biol Blood Marrow Transplant 2013 0.75
72 Does extra alemtuzumab remove the graft-versus-leukemia effect after allogeneic stem cell transplantation in chronic lymphocytic leukemia? Biol Blood Marrow Transplant 2009 0.75
73 Building a transplantation physician workforce for growing need: recruitment starts during residency. Biol Blood Marrow Transplant 2013 0.75
74 Umbilical cord blood transplant: expanding the options. Expert Rev Hematol 2013 0.75
75 Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. Semin Hematol 2012 0.75
76 Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric. Cornea 2017 0.75
77 Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric. Cornea 2016 0.75
78 Introduction: Why alternative donor transplantation and what are the different options and current challenges? Semin Hematol 2016 0.75